Literature DB >> 16544080

Bravo capsule induction of esophageal hypercontractility and chest pain.

C Tharavej1, J A Hagen, G Portale, C-C Hsieh, T A K Gandamihardja, J C Lipham, J H Peters, S R DeMeester, P F Crookes, C G Bremner, T R DeMeester.   

Abstract

BACKGROUND: The Bravo catheter-free pH monitoring system uses a capsule attached to the esophageal mucosa to detect acid exposure. Placement of the Bravo capsule is associated with intermittent chest pain in 50% of normal volunteers. The authors hypothesized that chest pain in this setting may be attributable to hypertensive esophageal contractions induced by the Bravo capsule.
METHODS: The study population consisted of 40 consecutive patients with reflux symptoms who had stationary esophageal manometry within 1 h after Bravo capsule placement. The control group consisted of 40 patients with symptomatic gastroesophageal reflux disease (GERD) from a population of patients with foregut symptoms who were computer matched to the study group for age, sex, lower esophageal sphincter (LES) pressure, LES length, and 24-h pH composite score. The patients in the control group had manometry before Bravo capsule placement. The occurrence of chest pain was assessed before and during the monitoring period by interview and review of the patient's diary. Mean contraction amplitudes in the distal third of the esophagus after 10 wet swallows were averaged. The prevalence of patients with esophageal contraction amplitudes in the distal third that exceeded the 95th percentile of normal (180 mmHg) and the mean amplitude of distal third esophageal contractions in the study and control populations were compared. In the study group, the incidence of chest pain among the patients with hypercontractility of the esophagus was compared with the incidence among those without hypercontractility.
RESULTS: The mean contraction amplitude was higher in the study group (144.7 vs 105.5 mmHg; p = 0.002). The number of patients with a mean distal esophageal contraction amplitude exceeding the 95th percentile of normal also was significantly higher in the study group (13/40 vs 5/40; p = 0.03). A total of 10 patients experienced new onset of chest pain with the Bravo capsule in place, and 6 patients experienced hypertensive esophageal contractions.
CONCLUSIONS: The intraesophageal Bravo capsule can cause hypertensive esophageal contractions, which may lead to chest pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16544080     DOI: 10.1007/s00464-005-0257-8

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  9 in total

1.  Systematic esophageal evaluation of patients with noncardiac chest pain.

Authors:  S J Chobanian; S B Benjamin; D J Curtis; E L Cattau
Journal:  Arch Intern Med       Date:  1986-08

2.  Effect of ambulatory 24-hour esophageal pH monitoring on reflux-provoking activities.

Authors:  R Fass; R Hell; R E Sampliner; G Pulliam; E Graver; V Hartz; C Johnson; P Jaffe
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

3.  High-amplitude peristaltic esophageal contractions associated with chest pain.

Authors:  M Traube; R Albibi; R W McCallum
Journal:  JAMA       Date:  1983-11-18       Impact factor: 56.272

4.  Esophageal manometrics in patients with angina-like chest pain.

Authors:  D L Brand; D Martin; C E Pope
Journal:  Am J Dig Dis       Date:  1977-04

5.  Feasibility and tolerability of transnasal/per-oral placement of the wireless pH capsule vs. traditional 24-h oesophageal pH monitoring--a randomized trial.

Authors:  W-M Wong; J Bautista; R Dekel; I B Malagon; I Tuchinsky; C Green; R Dickman; R Esquivel; R Fass
Journal:  Aliment Pharmacol Ther       Date:  2005-01-15       Impact factor: 8.171

6.  The effect of hiatus hernia on gastro-oesophageal junction pressure.

Authors:  P J Kahrilas; S Lin; J Chen; M Manka
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

7.  Ambulatory esophageal pH monitoring using a wireless system.

Authors:  John E Pandolfino; Joel E Richter; Tina Ours; Jason M Guardino; Jennifer Chapman; Peter J Kahrilas
Journal:  Am J Gastroenterol       Date:  2003-04       Impact factor: 10.864

8.  Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years' experience with 1161 patients.

Authors:  P O Katz; C B Dalton; J E Richter; W C Wu; D O Castell
Journal:  Ann Intern Med       Date:  1987-04       Impact factor: 25.391

9.  Diagnosis of nutcracker esophagus, segmental or diffuse hypertensive patterns, and clinical characteristics.

Authors:  M Pilhall; M Börjesson; P Rolny; C Mannheimer
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

  9 in total
  3 in total

1.  Wireless esophageal pH capsule for patients with gastroesophageal reflux disease: a multicenter clinical study.

Authors:  Xiao-Jun Yang; Tian Gan; Lei Wang; Zhuan Liao; Xiao-Hong Tao; Wei Shen; Xiao-Yan Zhao
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

2.  Clinical utility and tolerability of JSPH-1 wireless esophageal pH monitoring system.

Authors:  Jun-Nan Li; Chun-Lun Liu; Xiao-Hong Tao
Journal:  BMC Gastroenterol       Date:  2013-01-15       Impact factor: 3.067

3.  Reliability, Safety and Effectiveness of the Bravo(TM) Capsule: A Catheter-free pH Monitoring System for Evaluation of Gastroesophageal Reflux Disease in Children.

Authors:  Manoochehr Karjoo; Mirza Beg; Shannon Kesselring
Journal:  Middle East J Dig Dis       Date:  2012-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.